PharmaCyte Biotech, Inc.
PMCB
$1.04
$0.032.97%
NASDAQ
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -33.77% | -35.55% | -30.07% | -11.15% | -17.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -30.74% | -32.85% | -28.04% | -8.92% | -16.59% |
| Operating Income | 30.74% | 32.85% | 28.04% | 8.92% | 16.59% |
| Income Before Tax | -104.18% | 9,083.97% | 1,877.84% | 1,866.55% | 552.43% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -104.18% | 9,083.97% | 1,877.84% | 1,866.55% | 552.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -104.18% | 9,083.97% | 1,877.84% | 1,866.55% | 552.43% |
| EBIT | 30.74% | 32.85% | 28.04% | 8.92% | 16.59% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -143.26% | 261.76% | 165.15% | 186.96% | 201.54% |
| Normalized Basic EPS | -117.73% | 101.10% | 10,128.57% | 4,407.83% | 299.80% |
| EPS Diluted | -143.26% | 261.76% | 165.15% | 186.96% | 201.54% |
| Normalized Diluted EPS | -117.73% | 101.10% | 10,128.57% | 4,407.83% | 299.80% |
| Average Basic Shares Outstanding | -15.90% | -23.50% | -35.50% | -44.19% | -52.01% |
| Average Diluted Shares Outstanding | -15.90% | -23.50% | -35.50% | -44.19% | -52.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |